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A B S T R A C T
Despite signiﬁcant advances in pharmacological treatments, pulmonary arterial hypertension remains
an incurable disease with an unreasonably high morbidity and mortality. Although speciﬁc
pharmacotherapies have shifted the survival curves of patients and improved exercise endurance as
well as quality of life, it is also true that these pharmacological interventions are not always accessible
(particularly in developing countries) and, perhaps most importantly, not all patients respond similarly
to these drugs. Furthermore, many patients will continue to deteriorate and will eventually require an
additional, non-pharmacological, intervention. In this review we analyze the role of atrial septostomy
and Potts anastomosis in the management of patients with pulmonary arterial hypertension, we
summarize the current worldwide clinical experience (case reports and case series), and discuss why
these interventional/surgical strategies might have a therapeutic role beyond that of a ‘‘bridge’’ to
transplantation.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Idiopathic pulmonary arterial hypertension (IPAH) is charac-
terized by a progressive elevation of pulmonary artery pressure
(PAP), right heart dysfunction/failure, and untimely death [1,2]. It
has long been recognized that the survival of patients with IPAH
(formerly called primary pulmonary hypertension or PPH) clearly reserved.
Fig. 1. Despite similar levels of pulmonary artery pressures and pulmonary vascular resistances, patients with Eisenmenger syndrome show lower right atrial pressure and
higher cardiac index than those with primary pulmonary hypertension suggesting a better performance of the right heart in Eisenmenger syndrome.
Adapted from Hopkins et al. [9].
J. Sandoval et al. / Journal of Cardiology 66 (2015) 304–314 305depends on the adaptation of the right ventricle (RV) to increased
pressure-overload as many studies have demonstrated that the
variables assessing right ventricular function (or dysfunction) such
as right atrial pressure and cardiac index are the most powerful
predictors of mortality [1,2]. Indeed, the classic study by D’Alonzo
et al. reporting the results of the ﬁrst registry of the National
Institutes of Health of the USA demonstrated that PPH patients
with a cardiac index (CI) lower than 2.0 L min m2, or patients with
a mean right atrial pressure (mRAP) higher than 20 mmHg had
a dismal prognosis [1]. These ﬁndings have been validated by
contemporary [2] and modern studies and underscore the
importance of understanding RV biomechanics and cellular
physiology, in order to design integral treatment strategies for
patients with PAH.
There is no question that the advent of PAH-speciﬁc pharma-
cotherapies has shifted the survival curves of PAH patients. New-
generation therapies have been shown to improve exercise
endurance, quality of life, and survival [3]. However, it is also
true that these pharmacological interventions are not always
accessible (particularly in developing countries) and, perhaps most
importantly, not all patients respond similarly to these drugs
[3,4]. In fact, many treated patients will continue to clinically
deteriorate and will require interventional and/or surgical alter-
natives such as atrial septostomy (AS), Potts shunt, and lung
transplantation [3–6]. In the present review we analyze the role of
AS and Potts anastomosis in the management of PAH, we
summarize the current worldwide clinical experience, and discuss
why these interventional/surgical strategies might have a thera-
peutic role beyond that of a ‘‘bridge’’ to transplantation.
Atrial septostomy
Historical development and rationale
For some time now there has been clinical as well as
experimental evidence suggesting that in the setting of PAH an
inter-atrial right-to-left shunt may be of beneﬁt. From the clinical
point of view, we know that PAH patients with a patent foramen
ovale live longer than those without shunting [7]. We also know
that Eisenmenger patients with a comparable degree of pulmonary
hypertension live longer and do not develop severe RV dysfunctionwhen compared to patients with PAH [8,9]. Interestingly, Hopkins
et al. [9] have shown that despite having similar degrees of
pulmonary hypertension, patients with Eisenmenger syndrome
have a lower RAP and better CI than patients with PAH, reﬂecting
better RV performance (Fig. 1) [9]. It could be said that the idea
behind the creation of a right-to-left shunt at inter-atrial level (AS)
in patients with PAH was partly derived from the studies of
patients with Eisenmenger syndrome.
From the experimental point of view, the ﬁrst study supporting
the role of interatrial shunts was published by Austen et al. over
50 years ago [10]. This particular study is extraordinary not only
because it was the ﬁrst to show that an inter-atrial shunt in PPH
was beneﬁcial but also because they described most of the
knowledge we have about the physiological changes caused by AS.
In their original publication they described the results obtained
in 20 dogs with chronic RV pressure-overload, a model created in a
3-month period by progressive constriction of the pulmonary
artery with a band placed via thoracotomy as the ﬁrst intervention.
Through a second thoracotomy, the heart was exposed and
cannulated, connecting the superior vena cava with the left atria,
forming a right-to-left shunt. This shunt could be manipulated by
clamping. When the shunt was opened there was a signiﬁcant
decrease in RV and in right atrial (RA) pressures along with an
increase in cardiac output and systemic pressure. As expected,
there was also a decrease in arterial oxygen saturation (SaO2%). All
of these changes were reversed when the shunt was closed
(Fig. 2A).
A second set of experiments, performed in a separate group of
dogs, consisted of the surgical creation of an atrial septal defect
through a second operation in 50% of the dogs with the other
50% serving as the control group (sham group). Hemodynamic
measurements were performed 10 days after surgery and were
performed at rest and during mild and severe exercise as deﬁned
by running on a lead for 200 and 400 yards, respectively. These
dogs were previously trained to perform the exercises. Fig. 2B,
constructed with the data presented by the author, summarizes
the results of this experiment. Dogs with an atrial septal defect
were able to signiﬁcantly increase their cardiac output during both
mild and severe exercise at the expense of only a modest increase
in right ventricular end-diastolic pressure (RVEDP). On the other
hand, dogs in the control group not only did not increase cardiac
Fig. 2. Hemodynamic effects of an inter-atrial shunt in an experimental model of right ventricular hypertension. Acute hemodynamic effects at rest with the shunt open and
closed (A). Hemodynamic effects of an atrial septal defect (ASD) in dogs during mild (ME) and severe (SE) exercise (B). LV, left ventricular; RA, right atrial; RV, right ventricular;
RVEDP, right ventricular end-diastolic pressure.
Adapted from Austen et al. [10].
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exercise. A signiﬁcant number of dogs in the control group did not
tolerate severe exercise, and died during or immediately after the
test [10].
Austen et al. concluded that ‘‘the results of both groups of
experiments indicate that the presence of a R-to-L shunt at the
atrial level has the beneﬁcial effects of decompressing the
hypertensive RV and of augmenting systemic blood ﬂow’’ [10]. This
statement made more than 50 years ago has provided the
physiological rationale for AS. Austen et al. also suggested that
the shunt should be created at interatrial level and even proposed
this operation to be seriously considered for the management of
severe PPH [10]. An operation to create an interatrial shunt never
took place in part because William Rashkind (ﬁrst catheter-balloon
in 1966 [11]) and Sang C Park (ﬁrst blade-catheter in 1978 and
1982 [12,13]) described the techniques to create an atrial septal
defect without the need of a thoracotomy. These interventional
procedures were, and are still in use, mainly for the management
of several congenital heart diseases.
With accepted techniques to create an atrial septal defect, the
scenario was ready to attempt this procedure in the setting of
human PPH and, a year later, in 1983 Rich and Lam were the ﬁrst to
perform it [14]. The patient was a 22-year-old woman with severe
PPH, refractory to any type of vasodilator used at the time. She
received a Park blade AS that was completed with a Rashkind
balloon catheter technique. The patient tolerated the procedure
well; however, in the next 24 h she became agitated, and dyspneic.
The patient was hypoxemic and acidotic, developed refractory
systemic hypotension, and died. The autopsy of this patient
showed a 9 mm septostomy and signs of marked RV hypertrophy.
The left side of the heart was found markedly dilated and in the
lungs there were signs of pulmonary venous congestion, ﬁndings
that were interpreted as being the result of pulmonary edema due
to the sudden increase in preload to the left ventricle. Anotherpossibility to explain the death of the patient was severe refractory
hypoxemia, as the SaO2% signiﬁcantly decreased from 87% to 57%
after the procedure.
Perhaps as the consequence of a ﬁrst disappointing result, the
procedure remained relatively neglected until the report of the
ﬁrst series of patients in 1991 by Nihill et al. [15]. They performed
AS in 14 patients with severe PAH. There were two procedure-
related deaths in this series, again due to refractory hypoxemia, but
they also reported, for the ﬁrst time, 9 long-term survivors who
clinically improved after the procedure. The other important series
of AS in patients with PPH was that of Kerstein and colleagues from
Columbia University published in 1995 [16]. Kerstein et al. studied
15 patients with severe PPH in functional classes III and IV. Again
they used the combined procedure of blade-balloon AS (BBAS) in
most of the patients. They reported two procedural deaths but
also clinical improvement in most of the survivors. They were also
the ﬁrst ones to show that the long-term survival of PAH patients
with AS was better than that of historical controls.
As an attempt to decrease the procedure-related mortality, in
1998, our group [17] adopted the balloon dilation technique
[18,19], in a step-by-step manner, without the blade, to create the
interatrial shunt. We reported our initial experience in 15 patients
with idiopathic PAH, most of them in functional class IV. We had
only one procedure-related death and most of our patients had
an improvement in functional class, exercise endurance, and
predicted 3-year survival. Spontaneous closure of the defect was
a frequent ﬁnding in our series, so we performed a total of
22 independent procedures in these 15 patients without compli-
cations, with only one procedure-related death [17].
Balloon dilatation atrial septostomy
The procedure of balloon dilatation AS (BDAS) has been the
most employed technique in the past few years and it involves a
Fig. 3. BDAS technique. Perforation of the inter-atrial septum with the catheter and the Brockenbrough needle at the tip (A and B), a guidewire is passed to the left atrium
(C), over the guidewire a dilator (4 mm) is used as a ﬁrst dilation (D), the septostomy is completed with non-compliant balloons of different size ﬁlled with contrast media
(E and F).
From Sandoval et al. [6,17].
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needle and a Mullins’s dilator are used to perforate the septum, and
non-compliant peripheral balloons of different sizes are used to
perform the septostomy, in a controlled, ‘‘step-by-step’’ manner
(Fig. 3). Three minutes after each dilatation step is performed, we
measure and re-assess changes in hemodynamic variables in
particular the changes in SaO2% and left ventricular end-diastolic
pressure (LVEDP). The ﬁnal size of the shunt is limited by (1) the
drop in SaO2%, which should not be larger than 10% from baseline
and (2) by the increase in LVEDP, which should be kept below
18 mmHg [6]. When possible, a trans-esophageal echocardiogram
should be used to help visualize the precise site of puncture and
also to size the interatrial septostomy created (Fig. 4).
Worldwide clinical experience
It could be summarized that the clinical deterioration and death
of patients with IPAH is partly secondary to a drop in cardiac
output and systemic blood ﬂow, as well as congestion, dilation, and
failure of the right ventricle. Thus, the presence of an atrial septal
defect would, in theory, allow a right-to-left shunt-mediated
increase of cardiac output and would help decompress the right
ventricle, therefore ameliorating cardiac pump failure [20]. Based
on these premises, multiple hospitals around the world have
attempted the use of AS for the treatment of PAH. However, since
its ﬁrst report as a treatment for PAH over 30 years ago [14],
the precise role of AS in the management of PAH continues to be
relatively uncertain, mainly due to the fact that most of the
knowledge we have about the procedure comes from small cohorts
of patients, case reports, or non-controlled clinical trials. Further-
more, the indication for the procedure and the etiology of
pulmonary vascular disease [World Health Organization (WHO)
group] has not been the same in the patients reported. Lastly, the
advent of new pharmacological treatments of IPAH changed thetreatment algorithm [3,21] and new clinical trials are needed to
reduce any potential confounders when evaluating safety and
efﬁcacy of pharmacotherapies. Interestingly, despite all these
limitations, the experience with AS has increased in the past few
years.
In the most recent review of the worldwide experience [22],
372 procedures performed in 324 patients were identiﬁed;
304 have been reported in case series [15–17,23–43], and 20 as
case reports [18,19,44–61] (Table 1). AS has largely been
performed in young people, mostly women (70%), and most of
them with IPAH in functional classes III and IV (77%). Reports of
AS in patients with pulmonary hypertension associated with
surgically corrected congenital heart disease (9%), collagen tissue
disease (5%), and few cases of distal chronic thromboembolic
pulmonary hypertension (3.5%) have also been reported. Most
frequently, AS has been performed after failure of maximal medical
treatment in a signiﬁcant number of patients [22] (Table 1),
refractory congestive heart failure, recurrent syncope, or both
being the most common indications for the procedure.
Worldwide, different types of septostomies have been per-
formed (Table 2). Whether it is a BBAS, BDAS (No Park-blade
catheter is used), or a combination of both, it appears that BDAS
is the procedure of choice. The intervention has been repeated
in 48 occasions due to spontaneous closure of the defect. The size
of the defect has varied from 8 to 18 mm with mean value of
11 mm. Globally, overall 14% of the patients have died from
procedure-related complications, 8% deaths were immediate
(within 24 h due to refractory hypoxemia) and an additional 6%
within one month. However, most importantly, the large majority
of patients, that is 86%, survived the procedure with a 90%
improvement in functional capacity. Approximately 13% of the
patients received a lung transplant and in the long-term, 63
late deaths and 179 survivors were reported [22]. Table 3 shows
the variables associated with procedure-related mortality.
Fig. 4. Trans-esophageal echocardiography during atrial septostomy in a patient with pulmonary arterial hypertension allows visualization of the shunt created (arrow) and
permits the measurement of the defect. LA, left atrium; LV, left ventriculum; RA, right atrium; RV, right ventriculum.
From Kurzyna et al. [30].
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20 mmHg, remains, as shown in previous analyses [5,6,20], the
most signiﬁcant risk factor for death during the procedure. Low
SaO2% after the procedure, perhaps as a result of an oversized
septostomy, is also associated with a higher risk of death.
Hemodynamically, a modest but signiﬁcant decrease in RAP
(from 14.8  8 mmHg to 11.8  6.3 mmHg; p < 0.001), followed by a
similar increase in left atrial pressure (from 5.9  3.3 mmHg to
8.3 mmHg  4; p < 0.001) has been reported. Importantly, an
increased CI (from 2.0  0.68 L min m2 to 2.61  0.80 L min m2;
p < 0.001) and a signiﬁcant decrease in arterial oxygen saturationTable 1
Worldwide experience with atrial septostomy in the management of PAH.
Reference n Age Female NYH
Nihill et al. [15] 14 20.5  12.1 78.6% 3.8  0.
Sobrino et al. [23] 3 36.0  5.0 33% 4.0  0 
Kerstein et al. [16] 15 24.9  11.3 86.6% 3.53  
Rich et al. [25] 6 38.8  7.7 83.3% 3.7  0.
Thanopoulos et al. [24] 6 6.1  2.6 NA 3  0
Hayden [26] 6 35* 83.3% 4.0  0 
Sandoval et al. [17] 15 33  9 87% 3.6  0.
Rothman et al. [27] 12 37  12 83.3% 3.6  0.
Kothari et al. [28] 11 16.2  8.9 36% 3.62  
Reichenberger et al. [29] 17 35.9  14.2 70.6% 3.7  0.
Kurzyna et al. [30] 2 26.5  6.4 100% 4.0  0 
Allcock et al. [31] 9 56.4  22.4 100% 3.7  0.
Vachiery et al. [32] 16 NA NA 3.6  0.
Micheletti et l. [33] 20 8.4  5.6 55% 3.5  0.
Kurzyna et al. [34] 11 33.0  12 54.5% 3.3  0.
Ciarka et al. [35] 11 48.0  5 54.5% 3.5  0.
Law et al. [36] 43 12.5** 81% 3–4 
O’Byrne et al. [37] 5 29.4  10.5 60% 3–4 
Lammers et al. [38] 7 8.9  5.4 57% 3.1  0.
Troost et al. [39] 15 48.2  20.5 80% 4.0  0 
Fenstad et al. [40] 8 40.0  13 89% 3–4 
Sandoval et al. [41] 34 35.0  10 85% 3.5  0.
Vela´zquez Martı´n et al. [42] 7 NA 71% 3–4 
Baglini [43] 11 45.5  12 45.5% 3.6  0.
Total in series 304 30.7 years* 201/282 (71.6%) 3.9 W 0
Case reports [18,19,44–61] 20 30  13.5 13 (68.5%) 3.9  0.
Adapted from Ref. [22].
Abbreviations. NYHA: New York Heart Association Functional Class; CHF: Congestive 
* mean value.
** median value.(from 93.1  3.9% to 83.0  8.4%; p < 0.001) are usually reported.
Pulmonary and systemic pressures do not appear to change. It is
important to stress the fact that most of the hemodynamic variables
reported have been obtained during resting condition and the
hemodynamic status might be different during exercise when the
septostomy could be serving as a better ‘‘safety valve’’. The better
function of a septostomy during exercise might explain the
improvement in exercise endurance reported in many patient series
[17,31,32,39].
The hemodynamic effects of an AS also highly depend on the
baseline RAP. Table 4 shows how a higher baseline RAP will resultA Syncope CHF Both Procedures
4 5 6 3 14
3 3
0.52 7 8 16
5 6 6
 3 3 6
1 5 6
6 4 8 3 22
5 6 5 1 13
0.69 1 8 2 11




5 12 7 1 22
5 11 14
5 1 8 2 11
18 22 3 46
2 2 1 5
4 3 4 7
15 17
8 11
6 9 14 11 50
2 5 9
5 11 11
.3 86/288 (29.8%) 145/288 (50.3%) 57/288 (19.8%) 352
3 2 (20%) 10 (50%) 8 (40%) 20
heart failure; NA: not available.
Table 2
Type of septostomy and outcome in the worldwide experience.










Nihill et al. [15] 14 4 10 8–20 2 1 2 5 1 31.5 (0–96)
Sobrino et al. [23] 3 3 16  6 1 1 0–13 Mo
Kerstein et al. [16] 16 4 12 4–18 2 4 6 2 0–45 Mo
Rich et al. [25] 6 4 2 NA 2 1 3 NA
Thanopoulos et al. [24] 6 6 8.7  1.2 0 0 22 Mo (4–48)
Hayden [26] 6 6 NA 2 2 4 NA
Sandoval et al. [17] 22 22 10  3 1 1 2 5 16 Mo (0–36)
Rothman et al. [27] 13 13 10.2  1.3 2 1 2 5 5 0–18 Mo
Kothari et al. [28] 11 11 4–15 2 1 1 4 20 Mo (0–60)
Reichenberger et al. [29] 20 20 10.6  1.6 4 1 5 5 0–18 Mo
Kurzyna et al. [30] 2 2 7  1.4 1 0–5 Mo
Allcock et al. [31] 12 12 15.3  2.8 0 2 2 1 0–30 Mo
Vachiery et al. [32] 18 18 NA 1 1 1 3 NA
Micheletti et al. [33] 22 2 17 3 6.9  2.4 0 2 2 2 2.1 y (1 Mo–6.7 years)
Kurzyna et al. [34] 14 14 6.6  1.6 0 1 6 7 2 8.1 Mo (0.8–20.2)
Ciarka et al. [35] 11 11 15.2  2.7 0 NA
Law et al. [36] 46 30 5 11 12.2  2.9 2 8 9 19 3 1981–2005
O’Byrne et al. [37] 5 4 1 NA 0 4–216 days
Lammers et al. [38] 7 7 11.7  2.2 0 25.7 Mo (18–31)
Troost et al. [39] 17 17 4 (3–5) 1 2 3 6 4 0.7 year (0–5.9)
Fenstad et al. [40] 11 11 NA 0 1 1 2 1 243  183 days
Sandoval et al. [41] 50 50 8.5  2.5 1 21 22 58.5  38 Mo
Vela´zquez Martı´n et al. [42] 9 9 Mean 11 0 4 4 1 18 Mo (0–67)
Baglini [43] 11 11 NA 2 2 4 8.2  3.8 Mo
Series 352 40 (11.4%) 273 (77.5%) 39 (11%) Mean 10.8 24 (6.8%) 17 (4.8%) 62 102 35
Case reports [18,19,44–61] 20 14 6 8–18 mm 3 (15%) 2 (10%) 1 5 1 0–60 Mo
Total 372 40 287 45 27/372 (7.2%) 19/372 (5.1%)
Adapted from Ref. [22].
Abbreviations. Proc.: procedures; BDAS: balloon dilation atrial septostomy; BBAS: blade-balloon atrial septostomy; LT: lung transplant. Mo: months.
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RAP > 20 mmHg. However, as mentioned repeatedly in this
review, patients with a RAP > 20 mmHg will also have a
signiﬁcantly higher risk of death during the procedure as a result
of refractory hypoxemia. Thus, it appears that the best risk/beneﬁt
ratio corresponds to the group with a RAP between 10 and
20 mmHg. Nevertheless, the size of the septostomy should be
individualized when possible, as it should be noted that even when
RAP is lower than 10 mmHg there is a signiﬁcant increase in CI as
well as an improvement in functional class suggesting, perhaps,
that performing a septostomy at an early stage during disease
could also be of beneﬁt [22].Table 3




Age (years) 1.01 (0.990–1.037) 0.263
NYHA 2.82 (1.02–7.81) 0.045
Syncope 0.17 (0.04–0.75) 0.019
Right heart failure 3.09 (1.24–7.66) 0.015
Type, BDAS 1.51 (0.641–3.58) 0.343
Size (mm) 0.97 (0.797–1.24) 0.973
Baseline RAP (mmHg) 1.13 (1.07–1.19) 0.000
Baseline RAP > 20 mmHg 11.4 (3.75–34.7) 0.000
RAP after (mmHg) 1.18 (1.07–1.31) 0.001
Baseline PAP (mmHg) 1.03 (1.01–1.05) 0.001
LAP after (mmHg) 1.26 (1.07–1.48) 0.005
Baseline SaO2% 0.99 (0.88–1.11) 0.944
SaO2% after 0.91 (0.87–0.95) 0.000
Delta (decrease) SaO2% 1.09 (1.05–1.13) 0.000
Baseline Cardiac Index (L min m2) 0.32 (0.12–0.85) 0.022
Cardiac Index after (L min m2) 0.46 (0.64–1.32) 0.154
Delta (increase) Cardiac Index (%) 1.01 (1.006–1.03) 0.003
Abbreviation. LAP, left atrial pressure.What is the optimal size for septostomy?
As previously discussed, one of the main objectives of
septostomy is to increase systemic blood ﬂow and cardiac output;
however, a signiﬁcant increase in cardiac output after septostomy
might not always be beneﬁcial. Fig. 5 shows that there is a negative
correlation between the increase in CI and the drop in SaO2% after
septostomy, which prompts the question: what is the optimal size
for an AS?
Indeed, there is not a deﬁnitive answer: the size of the
septostomy should be individualized. We should aim to increase
cardiac output and to decompress the RV but refractory hypoxemia
should be avoided. Based on recent experimental data it would
appear that increasing cardiac output no more than 20% from
baseline would provide the best results and beneﬁts. In a study by
Zierer et al. [62], the effect of an inter-atrial shunt on right atrial
and RV mechanics was addressed. They used a canine model of RV
hypertension produced by banding, similar to that used by Austen
et al. many years ago [10]. Two degrees of shunting were explored:
low ﬂow, equivalent to 15% of the total cardiac output, and high
ﬂow representing almost 30% of the total output, which was
manipulated by controlling venous return. In their results, Zierer
et al. demonstrate that the slope of Emax in both chambers, that is,
cardiac contractility, did not change at any level of ﬂow but the
compliance, in particular the compliance of the right atrium,
increased especially at a low ﬂow. Apart from the improved
compliance of the right atrium, there was also a signiﬁcant shift
from the reservoir-to-conduit function ratio of the right atrium.
They also showed that as a result of the increase in LV preload by
the shunt, cardiac output and systemic oxygen delivery were also
increased except at high ﬂow where the beneﬁcial effects on
systemic oxygen delivery reversed. It could be said that the take-
home message from Zierer and collaborators’ work is that, when
performing a septostomy, we should try to keep the shunt between
15% and 20% of the baseline cardiac output at the most. Weimar
Table 4
Hemodynamic results and outcome after atrial septostomy according to baseline right atrial pressure.
Variable Baseline RAP < 10 (N = 27) p-value Baseline RAP 10–20 (N = 51) p-value Baseline RAP > 20 (N = 26) p-value
Age (years) 23  14 28  14 27.5  12
Syncope (%) 65.2% 26.2% 12%
RVF (%) 26% 33.3% 64%
Both (RVF + syncope) 8.7% 40.5% 24%
Before After Before After Before After
RAP (mmHg) 5.8  1.96 5.48  3.1 0.622 14.1  3.2 11.4  3.8 0.001 25.8  4.9 19.2  4.4 0.001
Cardiac Index (L min m2) 2.37  0.61 2.80  0.7 0.001 2.10  0.70 2.7  0.9 0.001 1.6  0.5 2.2  0.6 0.001
SaO2% 93.5  4.1 87.2  7.4 0.001 92.9  4.1 82.8  7.4 0.001 92.2  4.5 78.3  9.7 0.001
Mean PAP (mmHg) 62.8  17 64  19.6 0.588 64.9  16.7 65.6  16.7 0.617 64.8  23 69.9  24.7 0.185
Mortality 1-month 0/27 (0%) 2/51 (4%) 11/26 (42.3%)
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shunt fraction on cardiac output and oxygen delivery using
basically the same experimental model of pulmonary hypertension
[63]. They demonstrated that (1) a shunt ﬂow of 11% of the baseline
cardiac output increased cardiac function and oxygen delivery and
(2) arterial oxygen saturation decreased only when the shunt ﬂow
increased above 18%. Altogether, these two studies would suggest
that in severe PH, increasing a shunt fraction between 11% and 15%
of the baseline cardiac output would be the ideal target for an AS in
patients (Fig. 6).
Are there any direct beneﬁcial effects of atrial septostomy on the RV?
Whereas the main objective of an AS would be increasing
cardiac output and systemic blood ﬂow, decompression of the right
heart has been postulated. However, whether the RV is actually
‘‘decompressed’’ in patients after AS remains to be investigated.
Espı´nola-Zavaleta et al. [64] have shown that following AS, not only
there is a signiﬁcant reduction in right atrial but also a reduction in
both end-systolic and end-diastolic RV areas between 3 and
6 months after procedure, a ﬁnding that would be compatible with
the idea of decompression of the RV. Following the same line of
thought, a report from O’Byrne et al. has demonstrated a signiﬁcant
decrease in B-type natriuretic peptide (BNP) after septostomy [37],
suggesting a reduction in RV wall distention.
AS may also have other beneﬁcial direct effects on RV function.
Ciarka et al. [35] showed a signiﬁcant decrease in muscle
sympathetic nerve activity after the procedure. Sympathetic
overdrive exists in PAH and may be one of the mechanisms
involved in RV failure and poor prognosis [65,66]. Perhaps, a
decrease in sympathetic overdrive after AS could also reﬂect
decompression of the RV, as the drop in sympathetic activity after
AS correlated with a decrease in RAP [35]. Fig. 7 summarizes someFig. 5. Correlation between the change in cardiac index (delta CI%) and the change in
arterial oxygen saturation (delta SaO2%); r = 0.49; p  0.001.
Reproduced from Sandoval et al. [22].of the physiological effects of an AS in the setting of PAH. First, as a
result of the right-to-left shunt, there is an increase in left
ventricular preload and therefore an increase in cardiac output
[20,67,68], and second, there is decompression of the right heart
[37,64] which may decrease RV wall stress and oxygen demand,
and a possible improvement in RV performance, which in turn
contributes also to the increase in cardiac output.Fig. 6. Impact of shunt fraction on cardiac output (CO) and oxygen delivery in an
experimental model of right ventricular hypertension. In severe right ventricular
hypertension, a shunt ﬂow of 11% of the baseline cardiac output increased CO (A)
and oxygen delivery (DO2I) (B). Arterial oxygen saturation (SaO2) decreased only
when the shunt ﬂow increased above 18%, suggesting that in severe pulmonary
hypertension, a shunt of fraction between 11% and 18% of the baseline CO
represents the ideal shunt fraction to achieve in our patients.
Adapted from Weimar et al. [63].
Fig. 7. Summary of the potential physiological effects of balloon dilatation atrial septostomy. First, as a result of the right-to-left shunt, there is an increase in left ventricular
(LV) preload and therefore an increase in cardiac output. Secondly, there is decompression of the right heart, which decreases right ventricular (RV) wall stress and may in turn
improve RV performance and contribute to the increase in cardiac output.
Reproduced from Sandoval et al. [22].
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The indications for the procedure have not changed since 1998
[20], but have evolved from the time when no other options were
available to rescue the patient with severe RV failure after
maximal medical therapy. According to the latest WHO guidelines
[3], AS should be considered as a palliative procedure or as a
bridge in patients deteriorating despite maximal medical therapy.
The ideal candidate for AS would be a WHO class III patient, with
syncope or severe RV dysfunction despite maximal medical
therapy and the recommended procedure would be a step-by-step
BDAS.
Perhaps the biggest limitation of AS is that it should only be
performed in centers with established experience in both
pulmonary hypertension and AS. As mentioned, before the
procedure it will be critical to assure that the patient has an
arterial saturation higher than 90% on room air, and optimize
cardiac function. During the procedure a careful monitoring of
SaO2%, cardiac output, and LVEDP is mandatory and always
attempt a step-by-step procedure. After AS, oxygen delivery should
be optimized by securing an appropriate hemoglobin level by
blood transfusion or with erythropoietin treatment. Long-term
anticoagulation will also be necessary.
As mentioned before, according to the worldwide clinical
experience, spontaneous closure of septostomy is not an infre-
quent outcome presenting several months after the procedure
[22]. As an attempt to prevent spontaneous closure, Micheletti
and coworkers in England proposed the use of a fenestrated
Amplatzer [33], an approach that has been followed by others
[53,55,57,58]. An alternative approach would be to use a butterﬂy
stent as reported by Prieto [54] and others [39,61]. However, these
approaches have become controversial, as a follow-up publication
from the group using Amplatzer reported the occlusion of the
device in four out of nine patients despite the use of warfarin or
aspirin [38]. What promotes closure of the septostomy in somepatients but not others remains inconclusive. We have postulated
that the septostomy closes because the perforation was too small
or, as a consequence of decompression of the RV, the gradient of
pressure between the right and left atria decreases, thus promoting
closure as a physiological response. More recently, Guerrero et al.
[69] reported on the use of cryoplasty to freeze the borders of the
septostomy with the same objective: to maintain the septostomy
open. However, we do not know whether cryoplasty indeed
prolongs the patency of the defect or whether there are any long-
term complications.
Impact on long-term survival: effects of atrial septostomy combined
with pharmacotherapies
Based on the review of the worldwide collective experience, AS
stands as an additional strategy for the treatment of severe RV
failure from PAH. It improves hemodynamic variables that
correlate with clinical improvement and survival. In the majority
of patients, the procedure has been performed in an advanced
stage of disease with a signiﬁcantly higher risk of death, yet, in
spite of the severity of disease in these patients, the procedure
frequently leads to a clinical and hemodynamic improvement.
Unfortunately, the exact impact of septostomy on the survival of
the patients with PAH is difﬁcult to assess, as there are no
controlled long-term studies (something that it is also true for
most of the current pharmacological interventions). However, the
survival rates for patients with a long-term follow-up in different
case series appear to be better when compared with either
historical controls or predicted survival [16,17,36,39]. In addition,
the worldwide clinical experience suggests that the procedure-
related mortality is decreasing, perhaps as a consequence of
recommendations made during the PAH world symposium in 1998
[20]. Unfortunately, as it is the case for PAH-speciﬁc pharma-
cotherapies, there is a signiﬁcant drop of cumulative survival in
time, reﬂecting the palliative nature of the procedure. In other
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of the procedure wear off with time.
Another aspect that remains incompletely studied is the effect
of AS not only as a bridge, but also as an adjuvant to
pharmacotherapy. In a recent study, we have reported the long-
term effects of concomitant speciﬁc pharmacological treatment
after the septostomy in 11 out of 34 patients treated in our
institution [41]. It is important to underscore that, different from
most of the previous reports in the world literature, the
septostomy in these patients was performed at an earlier stage
and before the use of medical treatment. In our study, we
demonstrate that the survival of the group with septostomy plus
concomitant pharmacological treatment was signiﬁcantly better
than that of the group with septostomy alone (median survival:
83 vs. 53 months; log-rank 6.52; p < 0.01) suggesting a potential
beneﬁt from combining therapeutic strategies.
Potts anastomosis
This intervention, initially described many years ago for the
management of several forms of congenital heart disease, consists
of the anastomosis of the left pulmonary artery with the aorta
[70]. Potts anastomosis has been recently revived for the
management of PAH as a surgical alternative to AS based on a
similar physiological rationale: to increase systemic output and to
decompress the RV. Perhaps the main difference is that the right-
to-left shunt occurs at the post-tricuspid level, similar to what is
observed in patients with Eisenmenger Syndrome due to a patent
ductus arteriosus [71,72]. Theoretically, the main advantage of a
Potts anastomosis over an AS is that it creates a permanent post-
cardiac right-to-left shunt that does not lead to arterial oxygen
desaturation in the upper part of the body, including the brain and
the coronary circulation.
Blanc et al. [71] have described the use of this procedure in two
boys with supra-systemic pulmonary hypertension after an
arterial switch for transposition of the great arteries with
signiﬁcant post-operative improvement. In a subsequent commu-
nication from the same group of investigators, Baruteau et al. [72]
described the use of this intervention in eight children with supra-
systemic PH with functional class IV despite maximal medical
treatment. The procedure was performed via a left thoracotomy
without cardio-pulmonary bypass and the size of the shunt was
9 mm. Two patients who had interrupted medical treatment died
within two weeks after the procedure due to a hypertensive crisis,
but six children survived and remained with a good functional
class. Six-minute walking distance improved in all survivors and
the serum levels of BNP decreased almost to normal values.
Although creating a post-tricuspid shunt would be intuitive
based on data from Eisenmenger patients, it remains to be
investigated whether a post-tricuspid defect will prove to be
superior to an AS. Furthermore, to date, surgically created Potts
anastomoses have only been performed in children; however,
adults with severe RV failure might have a different post-operative
prognosis and higher peri-operative mortality. To by-pass the
potential risks associated with surgery, an innovative technique to
create a transcatheter Potts shunt (TPS) has been recently
described by Esch et al. [73]. In this report, four patients with
severe PAH underwent TPS under general anesthesia. Vascular
perforation was guided by ﬂuoroscopy and the shunt was created
via placement of a stent between the vessels. Although considered
technically successful in three cases, one patient died during the
procedure as a result of uncontrolled hemothorax and one more
died a few days later as result of ventilation-associated pneumonia.
The two survivors, however, had a signiﬁcant symptomatic
improvement and no late complications after 4 and 10 months
of follow-up were reported.Baruteau and coworkers have recently published a compendi-
um of their experience with both surgical anastomosis and TPS in
the management of PAH [74]. Their pooled data on 24 children
(1.5–17 years) who underwent a Potts shunt, 19 surgical, and
5 transcatheter, for drug-refractory PAH, show severe postopera-
tive complications occurring only in 6 patients (25.0% from the
surgical group) including 3 early deaths (12.5%) due to low cardiac
output. After a median follow-up of 2.1 years (range, 3 months
to 14.3 years) functional class dramatically improved in the
21 survivors (WHO-functional class I or II), mean 6-min walk
distance improved, none of the patients had experienced syncope,
and none had any reports of worsening of RV failure. The BNP/NT-
proBNP levels normalized in all patients. The authors concluded
that palliative Potts shunt prolonged survival and dramatically and
consistently improved functional class in children with severe,
drug-refractory PAH.
All together, it would appear that Potts anastomosis would be
an innovative approach for management of PAH and an alternative
to AS. However, more experience and reﬁnement of the technique
are required to reduce the risk of the procedures and to establish
TPS as a therapeutic modality for advanced PAH. Computed
tomography of the thorax prior to the procedure could help select
the ideal candidates for surgery as has been proposed by Guo et al.
[75] who described two types of relationships between left lower
pulmonary artery and descending aorta: in Type 1, the distance
between the vessels is minimal and in type 2 the distance is
greater, thus increasing the risk of bleeding. Theoretically, Type
1 patients make the better candidates for surgical anastomosis.
Non-invasive creation of an atrial septal defect
In the future, we anticipate seeing attempts to create a
septostomy noninvasively by means of histotripsy, which is an
ultrasonic technique that produces nonthermal, mechanical tissue
fractionation through the use of high-intensity ultrasound pulses
[76,77]. In a pilot study, Xu et al. applied this technique to create an
atrial septal defect in an open chest model in dogs [76]. With this
treatment they were able to produce a right-to-left interatrial
shunt in 9 of the 10 dogs, without signiﬁcant damage to the
surrounding tissues. Takey et al. have also been developing this
approach in alternative animal models with similar satisfactory
results [77]. However, human trials are warranted.
Conclusions and future directions
Despite signiﬁcant advances in pharmacological treatments,
PAH remains incurable. Interventional and surgical interventions
have been categorized as palliative treatments for PAH; however,
if we consider that (1) a palliative treatment is by deﬁnition
a ‘‘therapy that relieves or alleviates the problem but does not
treat the underlying cause’’ and (2) no current pharmacological
treatment has been shown to reverse or even prevent the
progression of vascular remodeling in patients with PAH (as it
has been elegantly shown by Stacher, Tuder and collaborators
[78]), one could ask which PAH-speciﬁc drug is not a palliative
treatment? It is true that the safety and efﬁciency of any
interventional/surgical therapy remain to be evaluated in a
controlled fashion, but the fact that these strategies improve
hemodynamics, quality of life, and prolong survival in a high-risk
population of PAH patients should not be overlooked. Unfortu-
nately, an adequately controlled study evaluating safety and
efﬁciency of any interventional therapy has been limited by the
relative success of PAH-speciﬁc treatments in recent years and
mainly by the lack of training/expertise worldwide. However, as
we observe the long-term evolution of patients treated after the
‘‘new medications era’’ and wait for the anticipated release of new
J. Sandoval et al. / Journal of Cardiology 66 (2015) 304–314 313targeted therapies into the drug pipeline, we should consider
additional strategies in an attempt to provide a more integral
support for the failing RV. Indeed, the potential beneﬁt of
combining interventional strategies such as septostomy with a
pharmacological treatment certainly deserves more attention in
the future. We strongly suggest that either surgical or interven-
tional strategies should be available in PAH-referral centers. It
remains a possibility that we are indeed taking too long to perform
any non-pharmacological strategy, and the optimal timing to use
them will have to be investigated in the coming years.
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